Other

Cubist Pharmaceuticals, Incorporated

American Harvest, Inc.

Merck Sharp + Dohme Corp.

Alternative Pioneering Systems, Inc.

Tibbar Plasma Technologies, Inc.

Merck + Co., Inc.

Trius Therapeutics, Inc.

Lawrence Livermore National Security, LLC

John F Finn

Min Teng

Michael Morytko

Dennis D Keith

Jason J Hill

Chad S Erickson

David A Dornbush

Sherman Tim Waddell

Milton L Hammond

Milana M Maletic

Gina M Santorelli

Aaron H Leeman

Jared Silverman

Tsvetelina Ivanova Lazarova

Alan D Watson

Ian Parr

Jim Siedlecki

Dale Christensen

Yan Zhang

Michael E Jung

Juan M Fernandez

Siya Ram

Junhu Zhang

Xiaoming Li

William A Gibson

Zhiyong Chen

Thanh To Lam

Michael Trzoss

Christopher John Creighton

Mark Hilgers

Liviu Popa-Simil

Daniel C Barnes

Richard Nebel

Keith Moser

Xian Yang Yu

Cihan Akcay

Aaron McEvoy

Leslie William Tari

Daniel Bensen

Yanzhi Zhang

Xiang Yang Yu

Douglas W Phillipson

Sergio E Wong

Felice C Lightstone

Suk Joong Lee

Paul L Gallant

Voon Ong

Toan B Nguyen

Mark Stidham

Philip A Wendler

Paul Aristoff

Zhongguo Wang

Hartmut Ginnow

Mark Cunningham

Lucy Aguirre Kohnen

Les Tari

Allen John Borchardt

An electrical transformer system using helical electrodes applied to a plasma. Systems and methods transform DC voltages and currents to different DC voltages and currents. Instead of using wires and iron cores similar to known transformers, the present DC to DC transformer system exploits plasma, helical electrodes, an axial magnetic field and radial magnetic field coils, with a control system to specify a radial magnetic field at the edge of a specified magnitude. A DC input voltage is applied, and an output is taken from electrodes at opposite the ends of the central apparatus. The system and apparatus contains a radial magnetic field embedded in the helical electrodes; the secondary current is taken from either solid or split (slotted) electrodes. Methods are disclosed for changing the output voltage and current relative to the input values. The system can function as either a stepup or a stepdown transformer.

DC to DC electrical transformer

An apparatus and corresponding systems and methods for managing electric power, particularly a transformer system and method, and more specifically a transformer for direct current. An example apparatus includes a chamber configured to contain plasma. The apparatus includes input electrodes disposed at least partially within the chamber, and configured to receive a first direct current input into the chamber. The input electrodes are configured to cause the input direct current to induce motion in the plasma. Motion induced in the plasma transforms current flowing there-through. At output electrodes extend from the chamber. The output electrodes conduct a second direct current, from the induced motion in the plasma, for delivery from the chamber.

DC-DC electrical transformer

An apparatus and corresponding systems and methods for managing electric power, particularly a transformer system and method, and more specifically a transformer for transforming direct current to alternating current. An example apparatus includes a chamber configured to contain plasma. The apparatus includes input electrodes disposed at least partially within the chamber, and configured to receive direct current input into the chamber. The input electrodes are configured to cause the input direct current to induce motion in the plasma. Motion induced in the plasma transforms current flowing there-through. Output electrodes extend from the chamber, which output electrodes may rotated in a controlled manner. The output electrodes conduct a three or one phase alternating current, from the induced motion in the plasma, for delivery from the chamber.

DC-AC electrical transformer

Novel gyrase inhibitors and related compositions and methods are useful for impeding bacterial growth. Compounds of Formula (I), are disclosed: Formula (I), wherein Y is N or CH; Z is N or CR; Ris H, a substituted or unsubstituted hydrocarbyl residue (1-3C) containing 0-2 heteroatoms selected from O, S and N, or is an inorganic residue; L is O, S, NR, or CRR; Ris H or Calkyl; Rand Rare each independently H or Calkyl; Ris H, a hydrocarbyl residue (1-40C) containing 0-10 heteroatoms selected from O, S and N optionally substituted with an inorganic residue; Ris H, an inorganic residue, or a hydrocarbyl residue (1-30C) containing 0-12 heteroatoms selected from O, S and N and containing 0-10 inorganic residues, wherein Rand Rtogether may join to form a fused ring; and Ris selected from the group consisting of H, Calkyl, Calkenyl, Calkynyl, halo Calkyl, halo Calkenyl, halo Calkynyl, Chydroxyalkyl, Calkyl chloride, Calkenyl chloride, and Calkynyl chloride; or a pharmaceutically-acceptable salt, ester, or prodrug thereof. 

Gyrase inhibitors

Novel gyrase inhibitors and related compositions and methods are useful for impeding bacterial growth. Compounds of Formula I are disclosed: 

The present disclosure provides compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R, Rand Z are as described herein. The disclosure also provides pharmaceutical compositions thereof; and methods for inhibiting DHFR activity; and methods for treating cell proliferative diseases, autoimmune disease, inflammatory disease or bacterial, fungal or parasitic infection by administering a compound of Formula I.

Dihydrofolate reductase inhibitors

The present invention relates to novel lipopeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel lipopeptide compounds and intermediates used in producing these compounds.

Lipopeptides as antibacterial agents

The present invention provides daptomycin stereoisomeric compounds, methods and intermediates for preparing daptomycin and daptomycin stereoisomoeric compounds, as well as pharmaceutical compositions of these compounds and methods of using these compositions as antibacterial agents.

Lipopeptide stereoisomers, methods for preparing same and useful intermediates

Lipopeptide stereoisomers, methods for preparing same, and useful intermediates

Prolines as antimicrobial agents

Catechols as antimicrobial agents

Growing community of inventors

Berlin, MA, United States of America

John F Finn